Last updated on February 2018

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Brief description of study

The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).

Clinical Study Identifier: NCT03124108

Contact Investigators or Research Sites near you

Start Over

George Mells, MD

Addenbrooke's Hospital
Cambridge, United Kingdom
  Connect »